Cellebrite (CLBT) lowers 2026 ARR and revenue guidance but raises EBITDA goal - Stock Titan

Cellebrite (CLBT) lowers 2026 ARR and revenue guidance but raises EBITDA goal Filing Impact (Neutral) Filing Sentiment (Neutral) Form Type 6-K Rhea-AI Filing Summary Cellebrite DI Ltd. appointed Shiven Ramji, previously President, Products and Technology, as Chief Executive Officer and Board member, succeeding Thomas E. Hogan in a planned transition effective immediately. For the quarter ended June 30, 2026, Cellebrite reported revenue of $131,138 thousand, up from $113,276 thousand a year earlier, with gross profit of $105,931 thousand and a gross margin of 80.8%. GAAP operating income was $6,949 thousand and net income was $6,371 thousand, while non-GAAP operating income reached $29,805 thousand and adjusted EBITDA was $31,790 thousand, a 24.2% adjusted EBITDA margin. Cash and cash equivalents were $141,250 thousand and total assets $994,311 thousand. Management stated that annual recurring revenue (ARR) was below expectations due to longer sales cycles and slower expansion from Inseyets conversions and therefore lowered full-year 2026 ARR and revenue outlook. For full-year 2026, Cellebrite now expects ARR of $550–$560 million with 14–16% annual growth, revenue of $555–$561 million with 17–18% annual growth, and raised its adjusted EBITDA target to $153–$159 million, implying an adjusted EBITDA margin of about 28%. Positive Q2 2026 revenue increased to $131.1M from $113.3M with gross margin of 80.8%, indicating strong top-line performance and high profitability on core operations. Non-GAAP profitability was robust, with Q2 adjusted EBITDA of $31.8M and margin of 24.2%, and full-year 2026 adjusted EBITDA guided to $153–$159M (~28% margin). The balance sheet shows solid liquidity, including $141.3M in cash and cash equivalents and total assets of $994.3M, supporting ongoing investment and growth initiatives. Management highlighted “healthy second-quarter growth” across Asia-Pacific, EMEA and U.S. Federal, and noted newer products are contributing more meaningfully to net new ARR than a year ago. Negative Management reported that ARR came in below expectations in Q2 2026, citing longer sales cycles and less expansion from Inseyets conversions than anticipated. The company lowered its full-year 2026 ARR outlook to $550–$560M with 14–16% annual growth, signaling softer-than-previously-expected recurring revenue momentum. Full-year 2026 revenue expectations were also reduced to $555–$561M, even as adjusted EBITDA guidance was raised, implying more conservative near-term top-line assumptions. GAAP operating margin declined year over year to 5.3% in Q2 2026 from 12.7% in Q2 2025, as operating expenses grew faster than gross profit under GAAP. Filing Explained The filing updates existing registration statements with GAAP tables but does not disclose a share offering, sale, or proceeds. As a Form 6-K, the August 13, 2026 filing furnishes interim material information and incorporates the release’s GAAP financial-statement tables by reference into three existing Form S-8 registration statements and one Form F-3. That action updates the financial disclosure associated with those registration statements; the filing does not report that shares were offered or sold, or that offering proceeds were received. The release separately identifies adjusted EBITDA and other non-GAAP measures as measures not prepared under GAAP and says they should not be treated as alternatives to GAAP operating income or net income. The relevant follow-up is a later filing or prospectus that specifically reports an offering, sale, or proceeds under the referenced registration statements; this filing reports no such transaction. Key Figures Q2 2026 Revenue: $131,138 thousand Q2 2026 Adjusted EBITDA: $31,790 thousand FY 2026 ARR Guidance: $550M–$560M +5 more 8 metrics Q2 2026 REVENUE $131,138 thousand For the three months ended June 30, 2026 Q2 2026 ADJUSTED EBITDA $31,790 thousand Non-GAAP adjusted EBITDA; margin 24.2% for Q2 2026 FY 2026 ARR GUIDANCE $550M–$560M Annual recurring revenue outlook with 14%–16% annual growth FY 2026 REVENUE GUIDANCE $555M–$561M Full-year 2026 revenue expectations with 17%–18% growth FY 2026 ADJUSTED EBITDA GUIDANCE $153M–$159M Raised full-year 2026 adjusted EBITDA target; ~28% margin CASH AND CASH EQUIVALENTS $141,250 thousand Balance as of June 30, 2026 TOTAL ASSETS $994,311 thousand Condensed consolidated balance sheet as of June 30, 2026 Q2 2026 GROSS MARGIN 80.8% Gross profit as a percentage of revenue for Q2 2026 Key Terms Annual recurring revenue, Adjusted EBITDA, Dollar-based net retention rate, Free cash flow, +2 more 6 terms Annual Recurring Revenue FINANCIAL Adjusted EBITDA FINANCIAL Dollar-Based Net Retention Rate FINANCIAL Free Cash Flow FINANCIAL Non-GAAP Financial Measures FINANCIAL Operating Lease Right-Of-Use Assets FINANCIAL AI-generated analysis. How Rhea-AI works. Not financial advice. Don't miss StockTitan's market coverage in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Form 6-K: How Foreign Companies Report to the SEC → AVAILABLE ON EDGAR 08/13/2026 - 07:15 AM ACCEPTED BY SEC EDGAR 08/13/2026 - 07:15 AM Learn about SEC filing dates FAQ What leadership change did Cellebrite (CLBT) announce in August 2026? Cellebrite appointed Shiven Ramji as Chief Executive Officer, effective immediately, succeeding Thomas E. Hogan. Ramji, who joined in May 2026 as President, Products and Technology, will also join the Board as part of a planned transition. How did Cellebrite (CLBT) perform financially in Q2 2026? In Q2 2026, Cellebrite reported revenue of $131.1M and gross profit of $105.9M with an 80.8% gross margin. GAAP net income was $6.4M, while adjusted EBITDA was $31.8M, representing a 24.2% adjusted EBITDA margin. What is Cellebrite’s full-year 2026 ARR guidance after the update? Cellebrite now expects full-year 2026 annual recurring revenue (ARR) of $550M–$560M, reflecting 14%–16% annual growth. Management noted ARR was below expectations in Q2 due to longer sales cycles and slower Inseyets expansion. What revenue outlook did Cellebrite (CLBT) provide for full-year 2026? For full-year 2026, Cellebrite guided to revenue of $555M–$561M, implying 17%–18% annual growth. This outlook incorporates a more measured view of near-term contributions from newer products amid elongated sales cycles. What adjusted EBITDA does Cellebrite target for 2026 after raising guidance? Cellebrite raised its 2026 adjusted EBITDA target to $153M–$159M, with an expected margin of about 28%. Management cited continued operating discipline and expects a stronger second-half free cash flow performance while funding growth investments. How strong is Cellebrite’s (CLBT) liquidity and balance sheet as of June 30, 2026? As of June 30, 2026, Cellebrite reported $141.3M in cash and cash equivalents, $300.5M in marketable securities (current and non-current), and total assets of $994.3M, against total liabilities of $456.2M. What guidance did Cellebrite give for Q3 2026? For Q3 2026, Cellebrite expects ARR of $524M–$528M with 19%–20% annual growth, revenue of $145M–$148M with 15%–17% growth, and adjusted EBITDA of $42M–$45M, implying a 29%–30% adjusted EBITDA margin. ⛶ Fullscreen Source: View Original Filing on SEC EDGAR Filing Exhibits & Attachments 1 document PRESS RELEASES EX-99.1 PRESS RELEASE TITLED "CELLEBRITE APPOINTS SHIVEN RAMJI CHIEF EXECUTIVE OFFICER, 252.3 KB